Allure Medical GLP-1 Review: Questions to Settle Before You Enroll

01Start by identifying the practice and the appointment

Allure Medical describes itself as a physician-led practice combining hormone health, wellness and cosmetic treatments. Its privacy policy identifies the business as Allure Medical Spa PLLC, doing business as Allure Medical. The website names Charles Mok, D.O., as founder and says he received his medical degree in 1989. These are the practice’s published descriptions, not independently verified credentials, and they do not identify which professional would evaluate or prescribe for a particular GLP-1 patient.

The broader weight-management catalog also lists Apollo ESG and the Orbera gastric balloon alongside GLP-1 treatment. That matters when booking: a general weight-loss consultation may involve discussion of several services rather than a specific medication pathway. Ask whether the appointment is expressly for the GLP-1 program, who conducts it, and whether the person discussing treatment options will also make the prescribing decision. A physician-led organization does not mean every consultation is with a physician.

Allure’s general website advertises same-day appointments and virtual telehealth visits. Its GLP-1 page advertises locations across three states, but does not define prescribing coverage or confirm that every appointment format applies to this program. Before sharing extensive health information, confirm the participating office, whether visits are in person or virtual, and whether care can continue from your state. The published location list is a starting point for that conversation, not evidence of nationwide access.

02Use the screening visit to establish what is being evaluated

The GLP-1 page describes a consultation and health review before a qualified healthcare professional makes an individualized recommendation. Its eligibility screening considers medical history, goals, BMI, current medications and risk factors. The initial consultation also addresses weight history and possible contraindications. This is more substantive than an advertisement offering medication alone, although the documentation does not specify appointment length, required tests, or how quickly a completed evaluation receives a clinical decision.

Allure describes the program as an option for adults with obesity or overweight accompanied by a weight-related condition. Its published reference points include BMI of 30 or higher, or 27 or higher with a weight-related condition. Those are screening descriptions, not a promise of acceptance. NIDDK likewise explains that general BMI thresholds do not replace individual evaluation. Allure cautions that treatment may not be appropriate during pregnancy or breastfeeding, when planning pregnancy, or with certain personal or family medical histories, including medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). These require discussion with the evaluating clinician. Allure does not publish a numerical minimum adult age in the consulted program material, so age requirements should be confirmed directly.

For preparation, the practice requests a medication and supplement list, relevant medical history, previous weight-loss programs, medications or surgeries, and information about nutrition, activity, sleep and stress. It specifically asks patients to disclose histories including diabetes, thyroid disease, pancreatitis, gallbladder problems, gastrointestinal issues and kidney disease. Bring this information for discussion rather than trying to decide eligibility yourself. Our consultation question organizer can help separate health-history questions from questions about price and service logistics.

03Ask for the medicine’s identity before comparing the offer

Allure clearly advertises injections and prescription GLP-1 medication, but the consulted pages do not identify active ingredients, brands, exact presentations or dispensing pharmacies. They also do not establish whether any offered preparation is compounded. The provider discusses approved medicines and possible off-label use in general terms without naming its actual products. A useful next step is to request the proposed medication’s complete name, formulation, presentation, intended use and pharmacy before treating this as comparable to another clinic’s offer.

FDA approval belongs to a particular drug product, not to Allure Medical or a pharmacy. If the proposed treatment is compounded, FDA explains that compounded preparations are not approved and do not undergo its premarket review for safety, effectiveness and quality. That distinction alone does not demonstrate clinical inequivalence. FDA recommends compounded drugs for patients whose medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nothing here establishes that Allure uses compounded treatment.

Allure also states that it is LegitScript certified, describing that certification as supporting compliance, transparency, advertising accuracy and patient safety. This review did not independently verify the claim, and it does not resolve which medicine a patient would receive. Keep the questions separate: practice representations, prescriber identity, product approval status and pharmacy responsibility each need their own answer. Our guide to identifying the medicine before comparing offers provides a framework for that discussion without assuming a particular treatment.

04Separate the GLP-1 bill from aesthetic advertising

The most visible numerical offer in the consulted general material is an aesthetic membership starting at $179 per month. It advertises free Botox, member pricing, priority booking and complimentary treatments. That is not a published GLP-1 rate, medication charge or weight-management subscription price. Separately, the general website advertises a free consultation without pressure or commitment, but the GLP-1 page does not expressly confirm that its evaluation is free. Ask which offer, if any, applies to the appointment being booked.

Allure says a personalized treatment plan outlines recommended treatments, realistic timelines and pricing. The public GLP-1 documentation does not supply amounts for medication, laboratory work, injection supplies or follow-up appointments, nor a supply period or billing interval. A written quote should distinguish the first charge from subsequent charges and identify what each payment buys. There is no basis here to calculate a monthly treatment total, assume an introductory discount, or describe an upfront payment as required.

General billing information discusses insurance-approved amounts and patient responsibility, but does not establish GLP-1 coverage, accepted plans for this program or prior-authorization assistance. NIDDK notes that weight-management medication coverage varies by plan; consultation coverage and medication coverage are separate questions. The table below turns the documented gaps into specific requests. For a fuller checklist, see our questions about costs beyond the monthly figure. Get the answers before authorizing a payment, not only after receiving a recommendation.

05Clarify what ongoing support actually looks like

Allure says an eligible patient receives an individualized plan and education about treatment, what to watch for and supportive habits. Allure lists possible common effects including nausea, vomiting, diarrhea, constipation, reflux, decreased appetite and abdominal discomfort. It also warns of potentially serious risks including pancreatitis, gallbladder problems, dehydration, kidney issues, allergic reactions and low blood sugar in certain patients, especially those using diabetes medications. Ask the clinician how the proposed medicine and your health history affect these risks. The program includes clinical monitoring and ongoing medical-team support, with progress reviewed and adjustments made when clinically appropriate. These are meaningful descriptions of intended care, but they are not an appointment schedule or service-level commitment. Ask when the first review occurs, what information the clinician reviews, and whether a scheduled visit is required before another prescription.

The program also describes nutrition, hydration, adequate protein, resistance training and regular movement as part of weight management. The documentation does not establish whether this guidance takes the form of written materials, individual counseling or appointments with a particular professional. Ask who provides it and whether those encounters are included in the quoted price. NIDDK describes medication as accompanying healthy eating and physical activity, with follow-up addressing tolerance and response rather than simply continuing payments.

Allure publishes phone, text and email contact routes, but no program-specific response times, clinical hours or escalation process. An administrative contact channel is not necessarily a route to the prescribing clinician. Ask how to raise a medication concern, who reviews that message, what happens outside office hours and whether additional clinical conversations cost extra. Our guide to support after the first prescription can help turn the broad promise of ongoing support into a practical communication plan.

06Locate the pharmacy and delivery responsibilities

The public GLP-1 pages do not name a dispensing pharmacy or explain whether patients collect medication, obtain it through an outside pharmacy, or receive delivery. Shipping fees, refrigeration arrangements, dispatch windows and arrival estimates are also undocumented. These gaps do not establish that delivery is unavailable. They mean a patient should ask who fills the prescription, how that pharmacy can be contacted, and which organization handles a delayed, damaged or incomplete order before relying on a delivery schedule.

If home delivery is offered, request the expected arrival process and the procedure for reporting a problem, including any replacement charges. A promised dispatch date would not itself establish arrival. For injectable GLP-1 drugs that arrive warm or with insufficient refrigeration, FDA explicitly advises not using the product and contacting the provider or dispensing pharmacy. That is general regulatory guidance, not a finding that Allure has had temperature-control problems or that every proposed product follows the same delivery route.

07Request enrollment terms beyond the text-message policy

The consulted page labeled Terms & Conditions largely concerns SMS communications. It does not provide a GLP-1 enrollment agreement detailing minimum commitments, automatic renewal, cancellation deadlines or refunds. Do not infer that the program is month-to-month, prepaid, nonrefundable or freely cancellable. Request the actual agreement and ask what happens if treatment is not recommended, a prescription changes, or you decide not to continue. Cancellation stops an obligation only under the applicable terms; it does not inherently promise a refund.

The SMS policy describes opt-in appointment reminders, confirmations, post-care instructions and aesthetic promotional offers. It says message and data rates may apply and message frequency depends on appointments. Those terms help explain one communication channel but do not establish clinical monitoring frequency or emergency availability. Confirm which messages are administrative, whether clinical questions can be sent by text, and what channel should be used for sensitive information. Ask separately about language assistance, accessibility accommodations and a patient portal, none of which is confirmed here.

08Resolve the privacy language before sending detailed records

Allure’s privacy policy says it collects personal details, medical conditions, treatments, prescriptions, medical photographs, laboratory results and billing information, with payment information collected by payment processors. It also describes third-party analytics and advertising technologies, including Google Analytics, Mixpanel and advertising networks using cookies and pixels. A practical question is where to submit clinical records securely and whether a general website inquiry form is the intended channel. The policy’s broad categories do not explain every data flow for an individual GLP-1 consultation.

The sharing language deserves clarification. One passage permits sharing with healthcare providers, pharmacies, service companies, advertising networks and joint marketing partners. Another says mobile or personal data is not sold or shared for third-party marketing and is shared only when strictly necessary to deliver services under confidentiality agreements. These statements are difficult to reconcile from the consulted text alone. Ask the practice which information is involved, which choices patients have, and how clinical communications are kept separate from promotional activity.

Questions & answers

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

1. FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
2. NIDDK: prescription medications for overweight and obesity ↗
3. Allure Medical — raleigh nc ↗
4. Allure Medical — privacy policy ↗
5. Allure Medical — raleigh nc/inside/weight management ↗
6. Allure Medical — about us ↗
7. Allure Medical — raleigh nc/outside/treatments/glp 1 agonist ↗
8. Allure Medical — terms conditions ↗

Continue reading

• GLP-1 Consultation Questions, Organized by Topic
• Ask What the Medicine Is Before Comparing the Offer
• Ten GLP-1 Price Questions Beyond “How Much per Month?”
• Who Can Answer Your Questions After the First GLP-1 Prescription?
• What Does a GLP-1 Program Need to Explain Before You Enroll?